Jeff Fairman - 07 Jun 2021 Form 4 Insider Report for Vaxcyte, Inc. (PCVX)

Role
VP, Research
Signature
/s/ Winston Macaraeg, Attorney-in-Fact
Issuer symbol
PCVX
Transactions as of
07 Jun 2021
Net transactions value
-$209,448
Form type
4
Filing time
09 Jun 2021, 16:53:58 UTC
Next filing
30 Jun 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PCVX Common Stock Options Exercise $290 +7,259 +141% $0.0400* 12,403 07 Jun 2021 Direct F1
transaction PCVX Common Stock Options Exercise $4,011 +2,241 +18% $1.79* 14,644 07 Jun 2021 Direct
transaction PCVX Common Stock Sale $213,750 -9,500 -65% $22.50 5,144 07 Jun 2021 Direct F2
holding PCVX Common Stock 341,227 07 Jun 2021 By Fairman Family Trust
holding PCVX Common Stock 50,000 07 Jun 2021 By AF 2020 Irrevocable Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PCVX Stock Option (right to buy) Options Exercise $0 -7,259 -100% $0.000000* 0 07 Jun 2021 Common Stock 7,259 $0.0400 Direct F3
transaction PCVX Stock Option (right to buy) Options Exercise $0 -2,241 -2.5% $0.000000 86,595 07 Jun 2021 Common Stock 2,241 $1.79 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 943 shares acquired under the Employee Stock Purchase Plan on May 17, 2021.
F2 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F3 The shares subject to the option are fully vested and exercisable.
F4 1/4 of the shares subject to the option vested on March 4, 2018, and 1/48th of the shares vest monthly thereafter.